PublisherInfo				
PublisherName		BioMed Central		
PublisherLocation		London		
PublisherImprintName	$\Box$	BioMed Central		

## Kinase mutations in cancer

ArticleInfo		
ArticleID	:	4500
ArticleDOI		10.1186/gb-spotlight-20020611-01
ArticleCitationID	$\Box$	spotlight-20020611-01
ArticleSequenceNumber	$\Box$	166
ArticleCategory	$\begin{bmatrix} \vdots \end{bmatrix}$	Research news
ArticleFirstPage	$\Box$	1
ArticleLastPage	$\Box$	2
ArticleHistory	:	RegistrationDate : 2002–6–11 OnlineDate : 2002–6–11
ArticleCopyright	:	BioMed Central Ltd2002
ArticleGrants	:	
ArticleContext		130593311

## Jonathan B Weitzman

Email: jonathanweitzman@hotmail.com

The RAS-RAF pathway regulates mitogenic signal transduction, and oncogenic *RAS* mutations are found in 15% of human cancers. In an Advanced Online Publication in Nature, Davies *et al.* describe results of a systematic genome-wide screen for mutations of genes in this pathway (9 June 2001, DOI:10.1038/nature00766). They found examples of somatic substitution mutations in the human *BRAF* gene in cancer cells. Analysis of over 500 cancer cell lines revealed a high mutation frequency in malignant melanomas, as well as mutations in a wide range of other tumor types. Mutant forms of the BRAF protein had elevated kinase activity, resulting in signalling and increased transforming capacity. Furthermore, Davies *et al.* found cancer cell lines that contain oncogenic mutations in both the *RAS* and *BRAF* genes, suggesting that tandem-activating mutations in more than one component of a signalling pathway may contribute to tumorigenesis.

## References

- 1. Control of the ERK MAP kinase cascade by Ras and Raf
- 2. *Nature*, [http://www.nature.com]

This PDF file was created after publication.